Ixabepilone: a new active chemotherapy in the treatment of breast cancer. Women's health (London, England) [Womens Health (Lond Engl)] Journal article | | Title | Ixabepilone: a new active chemotherapy in the treatment of breast cancer. | | Author(s) | Villanueva C, Vuillemin AT, Demarchi M, Bazan F, Chaigneau L, Pivot X | | Institution | University Hospital Jean Minjoz, Department of Medical Oncology, 25030 Besançon Cedex, France. cvillanueva@chu-besancon.fr , University Hospital Jean Minjoz, Department of Medical Oncology, 25030 Besançon Cedex, France. a.thieryvuillemin@mac.com , University Hospital Jean Minjoz, Department of Medical Oncology, 25030 Besançon Cedex, France. mdemarchi@chu-besancon.fr , University Hospital Jean Minjoz, Department of Medical Oncology, 25030 Besançon Cedex, France. ferbzn@hotmai.com , University Hospital Jean Minjoz, Department of Medical Oncology, 25030 Besançon Cedex, France. lchaigneau@chu-besancon.fr , University Hospital Jean Minjoz, Department of Medical Oncology, 25030 Besançon Cedex, France and, Institut National de la Santé et de la Recherche Médicale, Unit 645, 25000 Besançon, France. xavier.pivot@univ.fcomte.fr. | | Source | Womens Health (Lond Engl) 2009 Mar; 5(2):115-121. | | Abstract | Ixabepilone (BMS247550) is a semisynthetic derivative of the natural product that optimizes the properties observed with epothilone B. This compound has some similarities with taxanes in targeting and stabilizing microtubules, but it also has major differences. Interestingly, ixabepilone was evaluated in patients with well-characterized resistance to taxanes and was able to overcome the overexpression of multidrug resistance and was unaffected by mutations in the beta-tubulin genes. The interest in ixabepilone was clinically confirmed in Phase II and III clinical studies, which have demonstrated a strong activity in patients with metastatic breast cancer resistant to taxanes and in patients suffering from other types of chemoresistant tumors. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19245349 |
|
|
| |
Advertise on this site.
| | |
|
